Longeveron Inc.

What they do

Longeveron is a clinical-stage biotechnology company focused on regenerative medicines. Its lead investigational product, laromestrocel (Lomecel-B), is being evaluated in three primary indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease, and pediatric Dilated Cardiomyopathy. The company has no approved products and generates minimal revenue, primarily from grants and collaboration agreements.

Revenue drivers

• Grant revenue — Revenue from grants, such as those from the NIH/NHLBI for the ELPIS II trial, is a primary source; annual revenue was $1.2M in 2025 and $2.4M in 2024.
• Collaboration revenue — Limited collaboration or licensing revenue; recent quarterly revenue ranged from $137K to $398K in 2025-2026.

Recent performance

For the quarter ended June 30, 2026, revenue was $287,000, down from $398,000 in the prior quarter. Cash and equivalents were $10.1M as of June 30, 2026, up from $4.7M at the end of 2025, reflecting a $15.9M private placement in March 2026. Net losses have been consistent, with $22.7M net loss in 2025 and $16.0M in 2024. Operating cash flow was negative $18.6M in 2025.

Strategy

Longeveron is advancing laromestrocel through clinical development, with a focus on completing the Phase 2b ELPIS II trial in HLHS and preparing for a potential BLA submission for Alzheimer's disease. The company has secured FDA designations (Orphan, Fast Track, Rare Pediatric Disease) for HLHS and is planning a Phase 2 registrational trial for pediatric DCM, with initiation expected in 2027. Capital raising efforts, including equity offerings and a private placement, are intended to fund operations into the near term.

Risks

• Going concern risk — The company has a history of losses and an accumulated deficit of ~$132.3M; it expects to need additional capital to continue as a going concern.
• Clinical trial failure risk — ELPIS II and other trials may fail to meet endpoints, and there is no guarantee of regulatory approval for laromestrocel.
• Dilution risk — The company has raised capital through equity offerings, and the private placement includes conversion rights that can dilute existing shareholders.
• Cash runway risk — With cash of $10.1M as of June 30, 2026, and negative operating cash flows, the company may not have sufficient funds to complete all planned trials without additional financing.

Outlook

Management expects top-line results from the Phase 2b ELPIS II trial in HLHS in September 2026. The company also anticipates initiating a Phase 2 trial in pediatric DCM in 2027, with planning beginning in 2026. A Type B meeting with the FDA has supported a potential BLA pathway for Alzheimer's disease.